CN102846871A - 一种治疗肝火上炎型眶上神经痛的中药制剂及其制备方法 - Google Patents
一种治疗肝火上炎型眶上神经痛的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN102846871A CN102846871A CN2012103169614A CN201210316961A CN102846871A CN 102846871 A CN102846871 A CN 102846871A CN 2012103169614 A CN2012103169614 A CN 2012103169614A CN 201210316961 A CN201210316961 A CN 201210316961A CN 102846871 A CN102846871 A CN 102846871A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- preparation
- chinese medicine
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 31
- 230000001174 ascending effect Effects 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 109
- 208000002193 Pain Diseases 0.000 claims abstract description 78
- 230000036407 pain Effects 0.000 claims abstract description 76
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 241000208966 Polygala Species 0.000 claims abstract description 7
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 7
- 241000628997 Flos Species 0.000 claims description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 41
- 239000000843 powder Substances 0.000 claims description 23
- 241000522620 Scorpio Species 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241000237636 Pheretima Species 0.000 claims description 19
- 241000255791 Bombyx Species 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 8
- 238000000108 ultra-filtration Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 241001529739 Prunella <angiosperm> Species 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 235000012907 honey Nutrition 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- -1 sublimed preparation Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 58
- 210000004369 blood Anatomy 0.000 abstract description 57
- 206010019233 Headaches Diseases 0.000 abstract description 45
- 231100000869 headache Toxicity 0.000 abstract description 43
- 210000004185 liver Anatomy 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 27
- 210000001508 eye Anatomy 0.000 abstract description 24
- 230000001737 promoting effect Effects 0.000 abstract description 21
- 230000017531 blood circulation Effects 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000004087 circulation Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 241000239226 Scorpiones Species 0.000 abstract description 3
- 230000001914 calming effect Effects 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 2
- 235000006533 astragalus Nutrition 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000017965 Asarum canadense Nutrition 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000000385 Costus speciosus Nutrition 0.000 abstract 1
- 241000244365 Ligusticum sinense Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000157352 Uncaria Species 0.000 abstract 1
- 241000606265 Valeriana jatamansi Species 0.000 abstract 1
- 235000014687 Zingiber zerumbet Nutrition 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 244000112814 pipewort Species 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 201000010099 disease Diseases 0.000 description 32
- 239000009636 Huang Qi Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 18
- 239000009490 scorpio Substances 0.000 description 16
- 210000003128 head Anatomy 0.000 description 15
- 210000002216 heart Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 13
- 210000005036 nerve Anatomy 0.000 description 13
- 208000002173 dizziness Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000000582 semen Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 206010010774 Constipation Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000001314 paroxysmal effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 241000201295 Euphrasia Species 0.000 description 7
- 210000005252 bulbus oculi Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000036461 convulsion Effects 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 208000033809 Suppuration Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000002688 persistence Effects 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 206010015958 Eye pain Diseases 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000005392 Spasm Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 201000007227 lymph node tuberculosis Diseases 0.000 description 5
- 206010027599 migraine Diseases 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 208000001387 Causalgia Diseases 0.000 description 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 206010034960 Photophobia Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000007958 sleep Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 206010042772 syncope Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 3
- 239000010282 Emodin Substances 0.000 description 3
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 3
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 3
- 206010065952 Hyperpathia Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 208000001140 Night Blindness Diseases 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 3
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000002650 habitual effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 210000003901 trigeminal nerve Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000003695 paranasal sinus Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000009090 positive inotropic effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CBOKHFLBNZMMAA-UHFFFAOYSA-N Emodin anthrone Natural products OC1=CC(O)=CC2=CC3=CC(C)=CC(O)=C3C(O)=C21 CBOKHFLBNZMMAA-UHFFFAOYSA-N 0.000 description 1
- 241001112007 Eriocaulaceae Species 0.000 description 1
- 241000300213 Eriocaulon buergerianum Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000607292 Maguireothamnus speciosus Species 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001481692 Mesobuthus martensii Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241000157479 Nauclea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000157373 Uncaria rhynchophylla Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000001407 Vascular Headaches Diseases 0.000 description 1
- 201000006559 Vertebrobasilar insufficiency Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 201000010861 basilar artery insufficiency Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 108010038223 calciphorin Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001198 cardioexcitatory effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- LAJSXCAVRQXZIO-UHFFFAOYSA-N emodin anthrone Chemical compound C1=C(O)C=C2CC3=CC(C)=CC(O)=C3C(=O)C2=C1O LAJSXCAVRQXZIO-UHFFFAOYSA-N 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000103 occipital bone Anatomy 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001053 orthosympathetic effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229930189907 rotundine Natural products 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 235000019649 trigeminal effects Nutrition 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000009284 zhennaoning Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210316961.4A CN102846871B (zh) | 2012-08-31 | 2012-08-31 | 一种治疗肝火上炎型眶上神经痛的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210316961.4A CN102846871B (zh) | 2012-08-31 | 2012-08-31 | 一种治疗肝火上炎型眶上神经痛的中药制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102846871A true CN102846871A (zh) | 2013-01-02 |
CN102846871B CN102846871B (zh) | 2015-03-18 |
Family
ID=47394116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210316961.4A Active CN102846871B (zh) | 2012-08-31 | 2012-08-31 | 一种治疗肝火上炎型眶上神经痛的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102846871B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893701A (zh) * | 2014-04-13 | 2014-07-02 | 夏鲲鹏 | 一种减轻外科手术后病人疼痛及促进伤口愈合的中药组合物 |
CN104474462A (zh) * | 2014-11-25 | 2015-04-01 | 青岛恒波仪器有限公司 | 一种治疗三叉神经痛的中药制剂及其制备方法 |
CN104958445A (zh) * | 2015-07-14 | 2015-10-07 | 青岛恒波仪器有限公司 | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108114A (zh) * | 1994-04-05 | 1995-09-13 | 戚嘉和 | 一种治疗三叉神经痛的中药-舒容三叉安 |
CN100998733A (zh) * | 2006-12-28 | 2007-07-18 | 王玉秀 | 一种治疗久病入络型三叉神经痛的内服中药 |
CN101224278A (zh) * | 2008-01-14 | 2008-07-23 | 北京中科雍和医药技术有限公司 | 一种治疗原发性三叉神经痛的药物组合物及其制备方法 |
CN101269160A (zh) * | 2008-04-03 | 2008-09-24 | 徐恒雁 | 一种治疗三叉神经痛的中药组合物 |
CN101549104A (zh) * | 2008-04-03 | 2009-10-07 | 北京中科仁和科技有限公司 | 一种治疗三叉神经痛的中药组合物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108114C (zh) * | 2000-07-25 | 2003-05-14 | 陈光者 | 羚羊鱼脑饮品的制作方法及其产品 |
-
2012
- 2012-08-31 CN CN201210316961.4A patent/CN102846871B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1108114A (zh) * | 1994-04-05 | 1995-09-13 | 戚嘉和 | 一种治疗三叉神经痛的中药-舒容三叉安 |
CN100998733A (zh) * | 2006-12-28 | 2007-07-18 | 王玉秀 | 一种治疗久病入络型三叉神经痛的内服中药 |
CN101224278A (zh) * | 2008-01-14 | 2008-07-23 | 北京中科雍和医药技术有限公司 | 一种治疗原发性三叉神经痛的药物组合物及其制备方法 |
CN101269160A (zh) * | 2008-04-03 | 2008-09-24 | 徐恒雁 | 一种治疗三叉神经痛的中药组合物 |
CN101549104A (zh) * | 2008-04-03 | 2009-10-07 | 北京中科仁和科技有限公司 | 一种治疗三叉神经痛的中药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
朱新民等: "针药并用治疗原发性眶上神经痛疗效观察", 《中医药临床杂志》, vol. 17, no. 04, 28 August 2005 (2005-08-28), pages 368 - 369 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893701A (zh) * | 2014-04-13 | 2014-07-02 | 夏鲲鹏 | 一种减轻外科手术后病人疼痛及促进伤口愈合的中药组合物 |
CN103893701B (zh) * | 2014-04-13 | 2016-03-30 | 夏鲲鹏 | 一种减轻外科手术后病人疼痛及促进伤口愈合的中药组合物 |
CN104474462A (zh) * | 2014-11-25 | 2015-04-01 | 青岛恒波仪器有限公司 | 一种治疗三叉神经痛的中药制剂及其制备方法 |
CN104958445A (zh) * | 2015-07-14 | 2015-10-07 | 青岛恒波仪器有限公司 | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102846871B (zh) | 2015-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN103041264B (zh) | 一种防治血管性痴呆葛根补脑益智口服液及其制备方法 | |
CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
CN103041209A (zh) | 一种治疗肾阴虚的中药制剂及其制备方法 | |
CN104758839A (zh) | 一种治疗紧张性头痛的中药药丸及制备方法 | |
CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
CN104825914A (zh) | 一种辅助治疗乳腺癌症的中药制剂 | |
CN104173773A (zh) | 偏头痛祛风活血制剂及制备方法 | |
CN101700336B (zh) | 一种治疗颅脑外伤后遗性头痛的中药制剂及其制备方法 | |
CN102846871B (zh) | 一种治疗肝火上炎型眶上神经痛的中药制剂及其制备方法 | |
CN104173517A (zh) | 治疗原发性三叉神经痛的中药制剂及制备方法 | |
CN104547598A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN102048913B (zh) | 一种治疗更年期综合症的中药制剂及其制备方法 | |
CN101732685A (zh) | 一种针灸用的皮肤表面浸润中药制剂 | |
CN103830558A (zh) | 一种抗衰老组合物及其制备方法 | |
CN103432274B (zh) | 一种治疗偏头痛的药物及其制备方法 | |
CN104857370A (zh) | 一种治疗乳腺癌症的中药组合物 | |
CN105169265A (zh) | 一种治疗偏瘫的中药组合物及其制备方法 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN102743709B (zh) | 一种治疗风邪入侵眶上神经痛的中药制剂及其制备方法 | |
CN104162112B (zh) | 一种药物组合物及其制备方法 | |
CN105288298A (zh) | 一种用于脑动脉瘤后遗症的中药制剂及其制备方法 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
CN105311527A (zh) | 一种用于治疗子宫内膜移位症的中药制剂及其制备方法 | |
CN104706942A (zh) | 一种治疗脑心综合征的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Sun Peng Inventor after: Yu Faao Inventor after: Jiang Zhijuan Inventor after: Liu Junhua Inventor after: Wang Jun Inventor before: Wang Jun |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG JUN TO: SUN PENG YU FAAO JIANG ZHIJUAN LIU JUNHUA WANG JUN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171023 Address after: 401120, 5-, Yubei District, Chongqing, 1 Dragon Street 498 Patentee after: Chongqing Kai Tuo development in science and technology company limited Address before: 266033 No. 138, Liu Liu Road, Sifang District, Shandong, Qingdao Patentee before: Yang Gaolin |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201109 Address after: 226400 Chengcha Town Industrial Concentration Zone, Rudong County, Nantong City, Jiangsu Province Patentee after: Liu Jun Address before: 401120 Jiale Ziguang Building 5-Business, 498 Hongjin Avenue, Longxi Street, Yubei District, Chongqing Patentee before: CHONGQING KAITUO TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right |